Breaking Down Creative Medical Technology Holdings, Inc. (CELZ) Financial Health: Key Insights for Investors

You're looking at Creative Medical Technology Holdings, Inc. (CELZ) and seeing a classic high-risk, high-reward biotech play, but you need to know the near-term financial reality before placing a bet. Honestly, the Q3 2025 report shows a company operating on pure clinical potential, not sales, with trailing twelve months (TTM) revenue ending September 30, 2025, at a mere $6.00K, while the net loss for the nine months ended September 30, 2025, ballooned to $4.11 million. That burn rate is the immediate risk, but the recent good news is the October 2025 announcement of warrant exercises bringing in $4.2 million in gross proceeds, plus the August 2025 FDA Fast Track designation for their lead therapy, CELZ-201-DDT, a major catalyst that could defintely change the valuation equation, so let's dig into whether their $6.54 million in cash and equivalents from the last reported quarter is enough runway to hit the next critical clinical milestone.

Revenue Analysis

You need to look past the top-line number for Creative Medical Technology Holdings, Inc. (CELZ) because this is a clinical-stage biotechnology company, not a commercial powerhouse yet. The current revenue is minimal and volatile, driven by a small portfolio of commercial-stage products while the core value lies in the development pipeline.

The company's revenue streams are straightforward but extremely small, stemming almost entirely from its commercial offerings in the regenerative medicine space. These are primarily the CaverStem kit, which treats erectile dysfunction, and FemCelz, for addressing loss of genital sensitivity and dryness. To be fair, these products represent a tiny fraction of the company's overall focus, which is on its ImmCelz and AlloStem platforms in clinical trials.

For the trailing twelve months (TTM) ending September 30, 2025, Creative Medical Technology Holdings, Inc.'s revenue stood at just $6,000. This is a significant indicator of its pre-commercial status. For a more direct 2025 snapshot, sales for the first nine months ended September 30, 2025, totaled only $3,000.

Here's the quick math on recent performance, which shows a clear contraction in the small commercial segment:

• Year-over-Year Revenue Decline: The TTM revenue of $6,000 ending September 30, 2025, was down -45.45% compared to the $11,000 annual revenue reported for 2024.
• Nine-Month Comparison: The $3,000 in sales for the nine months ended September 30, 2025, is a -62.5% drop from the $8,000 reported in the same period a year prior.
• Quarterly Volatility: Q3 2025 revenue was reported as $0, highlighting the sporadic nature of sales.

The growth rate is negative, but that's not the whole story.

What this estimate hides is that the company's real 'business segment' is research and development (R&D). The commercial products like CaverStem and FemCelz generate revenue, but they are not the primary value driver. The overwhelming majority of the company's capital and attention is directed toward its clinical pipeline, such as the ImmCelz platform for immunotherapy and AlloStem for indications like chronic lower back pain, which are not generating revenue yet. The $11,000 in annual revenue for 2024 was primarily from CaverStem kits. This means the commercial segment is the only one contributing revenue, and its contribution to overall revenue is 100%, but its contribution to company value is arguably minimal compared to the pipeline.

The significant change in the revenue stream is the shift from any meaningful commercial sales to a near-zero revenue environment as the company focuses intensely on its clinical trials. This is a common, though risky, pivot for small biotech firms. If you want to dive deeper into who is betting on this pipeline, you should be Exploring Creative Medical Technology Holdings, Inc. (CELZ) Investor Profile: Who's Buying and Why?

The table below summarizes the sales performance, which is a key risk indicator for short-term liquidity, even if the long-term thesis is tied to R&D success.

Your action here is to defintely track R&D milestones and cash burn, not revenue growth, as the latter is irrelevant until a core platform like ImmCelz or AlloStem is commercialized.

Profitability Metrics

You're looking at Creative Medical Technology Holdings, Inc. (CELZ), and the first thing to understand is that its profitability metrics are typical of a clinical-stage biotechnology company: high gross margin but deep losses further down the income statement. This isn't a surprise, but the numbers themselves are stark, and we need to map the risks.

For the trailing twelve months (TTM) ending September 30, 2025, Creative Medical Technology Holdings reported minimal revenue of just $6.0 thousand. This low top-line figure is the primary driver of the massive negative margins, as the company's operating expenses far outweigh its sales.

Here's the quick math on their core margins for the TTM ending Q3 2025:

• Gross Profit Margin: The company maintains a strong gross margin of 60.00%. This means for every dollar of product sold, $0.60 is left after covering the direct cost of goods sold. This is a good sign for the underlying product economics, but it's built on a tiny revenue base.
• Operating Profit Margin: This is where the development costs hit. The operating margin is a staggering -101,379.43%. The TTM operating loss was about $6.08 million. This is the cost of running a research and development (R&D) heavy business with almost no sales.
• Net Profit Margin: The net profit margin is similarly deep in the red, at approximately -99,356.8%. The TTM net loss was around $6.0 million. This loss reflects the company's core focus on advancing its clinical pipeline, such as the FDA Fast Track Designation for CELZ-201-DDT, rather than commercial sales. You can read more about their strategic focus here: Mission Statement, Vision, & Core Values of Creative Medical Technology Holdings, Inc. (CELZ).

Profitability Trends and Operational Efficiency

Looking at the trend, the picture is one of a company still in the heavy investment phase. The TTM revenue of $6.0 thousand ending Q3 2025 is a sharp drop from the fiscal year 2024 annual revenue of $11.0 thousand. Also, the TTM net loss of $6.0 million is slightly worse than the $5.5 million annual loss reported for the full fiscal year 2024. The good news is that the Q2 2025 net loss of $1.23 million narrowed by 21% compared to Q2 2024, showing some quarterly improvement in expense management or a slight revenue bump.

Operational efficiency, outside of the gross margin, is all about cost management (or 'burn rate') in this sector. The high 60.00% gross margin is defintely a positive indicator of efficient production costs relative to the small amount of product they do sell. The real operational challenge is controlling the massive selling, general, and administrative (SG&A) and R&D expenses that drive the multi-million dollar operating loss. That's the reality of a company focused on clinical trials and development, not commercial scale.

Industry Comparison: A Different Ballgame

You need to compare Creative Medical Technology Holdings not to a mature, profitable business, but to the industry average for established players to understand the long-term goal. The contrast is dramatic. For instance, the average Return on Equity (ROE) in the broader pharmaceutical industry is approximately 10.49%. Creative Medical Technology Holdings' TTM ROE, however, sits at a deeply negative -98.14%.

This massive gap highlights the binary nature of biotech investing. The company is currently destroying shareholder equity (negative ROE) as it funds its clinical programs. The investment thesis here hinges entirely on a future product breakthrough that would flip the net income from a $6.0 million loss to a multi-million dollar profit, thereby making the margins and ROE competitive. Until then, you are buying a lottery ticket on the pipeline, not a stake in a profitable operation.

Debt vs. Equity Structure

You want to know how Creative Medical Technology Holdings, Inc. (CELZ) is funding its operations, and the short answer is: almost entirely through equity, not debt. For a clinical-stage biotechnology company, this is a common and often preferred strategy. It means the company is largely avoiding the fixed interest payments and principal obligations that come with debt, which can be a major risk when revenue is minimal.

As of the most recent quarter in 2025, Creative Medical Technology Holdings, Inc. carried a remarkably low level of debt. Total debt was only about $14.19 thousand, and crucially, the company reported having no long-term debt on its balance sheet. This minimal debt load is dwarfed by its cash position, which stood at approximately $5.38 million. They have more cash than total liabilities, which is a great starting point.

Here's the quick math on leverage: The company's Debt-to-Equity (D/E) ratio is approximately 0.25% (or 0.0025). This is an extremely low leverage ratio. For context, the average Debt-to-Equity ratio for the Biotechnology industry in the US, as of November 2025, is around 0.17 (or 17%). Creative Medical Technology Holdings, Inc. is operating at a fraction of the industry average, which points to a very conservative approach to financing.

The company's financing strategy is clearly focused on equity funding to fuel its clinical development and commercialization efforts. This is typical for a biotech firm that is pre-profitability and needs capital for research and trials. Recent actions confirm this preference for equity over debt:

• Warrant Exercises: In late October 2025, the company announced agreements for the immediate exercise of existing warrants, generating gross proceeds of approximately $4.2 million.
• Registered Offerings: They have also relied on registered direct offerings, like the $1.85 million offering in late 2024, to raise capital.

What this estimate hides is the potential for shareholder dilution (the reduction in ownership percentage for existing shareholders) that comes with issuing new shares or warrants to raise capital. Since they have no credit ratings and no recent debt issuances or refinancing activity, the focus for investors should be on the burn rate of their cash reserves and the milestones achieved from this equity funding. The trade-off for low debt risk is a higher reliance on the capital markets, which can be volatile for a small-cap stock. To dive deeper into the full picture, you should check out Breaking Down Creative Medical Technology Holdings, Inc. (CELZ) Financial Health: Key Insights for Investors.

The defintely low debt level gives Creative Medical Technology Holdings, Inc. flexibility, but the ongoing need for capital to fund clinical trials means they will likely continue to tap equity markets, so watch for future share issuances.

Liquidity and Solvency

You need to know if Creative Medical Technology Holdings, Inc. (CELZ) has enough cash to fund its research and development (R&D) pipeline, and the short answer is yes, for now. The company's liquidity position is exceptionally strong, driven by recent financing, but its core business still burns cash, which is a key risk to monitor.

The high liquidity ratios are a clear sign of financial strength. As of the Most Recent Quarter (MRQ) in 2025, the company's Current Ratio-which measures current assets against current liabilities-stands at a remarkable 20.71. A ratio over 2.0 is generally considered excellent, so 20.71 is a massive cushion. The Quick Ratio (or acid-test ratio), which excludes inventory for a stricter view, is nearly identical at 20.57. This tells us that nearly all current assets are highly liquid, like cash or short-term investments, which is typical for a pre-commercial biotech firm with minimal product sales.

This strong liquidity translates directly into a positive working capital trend. Working capital (current assets minus current liabilities) was approximately $5.8 million as of December 31, 2024, and the 2025 MRQ ratios suggest this position has been maintained or improved. The company is defintely not struggling to meet its near-term obligations; it has a significant buffer. You can find more on the company's long-term strategy here: Mission Statement, Vision, & Core Values of Creative Medical Technology Holdings, Inc. (CELZ).

However, the cash flow statement shows the real operational challenge. For the Trailing Twelve Months (TTM) ended in the first half of 2025, Creative Medical Technology Holdings, Inc. (CELZ) reported a negative Cash Flow from Operating Activities of approximately -$5.69 million. This negative number is normal for a development-stage biotechnology company, as they spend heavily on R&D before generating significant revenue. The Investing Cash Flow TTM was only -$0.2 million, indicating minimal capital expenditure, which is expected.

The primary source of cash is Financing Activities. In October 2025, the company announced agreements for the exercise of warrants, bringing in gross proceeds of $4.2 million. This is the capital that funds the operating loss and keeps the liquidity ratios so high. Here is a quick look at the TTM cash flow trends:

The key takeaway is that the company's liquidity strength is entirely dependent on its ability to raise capital through financing, like the recent warrant exercise. The current cash position of $5.38 million (MRQ) combined with the new $4.2 million infusion provides a runway, but the $5.69 million annual cash burn means they will need to return to the capital markets within the next 12 to 18 months, assuming the burn rate is constant. This financing dependency is the single biggest liquidity concern for investors.

Valuation Analysis

You're looking at Creative Medical Technology Holdings, Inc. (CELZ) and wondering if the stock is a bargain or a trap. The quick answer is that traditional valuation metrics suggest the company is priced based on future potential, not current earnings, which is typical for a clinical-stage biotechnology firm. Given the current stock price of roughly $3.05 as of mid-November 2025, and a highly variable analyst price target, the market is defintely pricing in a significant amount of risk and potential upside.

When a company isn't profitable, standard ratios like Price-to-Earnings (P/E) become meaningless, or in this case, negative. The trailing twelve-month (TTM) P/E ratio for Creative Medical Technology Holdings, Inc. (CELZ) sits at about -1.03x, and the Enterprise Value-to-EBITDA (EV/EBITDA) is also not applicable because the TTM EBITDA is negative, around -$5.97 million. This simply tells you they are burning cash to fund development, which is the reality of the biotech game.

A better anchor for this stage is the Price-to-Book (P/B) ratio, which compares the stock price to the company's book value (assets minus liabilities). Creative Medical Technology Holdings, Inc. (CELZ)'s P/B ratio is a modest 1.41. This means the stock is trading at 1.41 times its net tangible assets, which isn't wildly expensive for a company with intellectual property and clinical programs. It's a good sign that the price isn't entirely divorced from the balance sheet.

Stock Performance and Analyst Sentiment

The stock has been a roller coaster, which is par for the course in this sector. Over the last 12 months, the stock price has increased by about 10.97%, but this hides massive volatility. The 52-week trading range has spanned from a low of $1.69 to a high of $6.90. That kind of range means you have to have an iron stomach and a long-term view.

For the 2025 fiscal year, analysts expect a consensus Earnings Per Share (EPS) forecast of -$2.03, reflecting that ongoing investment in their pipeline. Also, don't look for passive income here: Creative Medical Technology Holdings, Inc. (CELZ) does not pay a dividend, so the dividend yield and payout ratios are 0.00%.

Analyst consensus is currently a 'Reduce' rating, which is a cautious signal. However, price targets are all over the map, which shows the inherent uncertainty in valuing a biotech company before a major drug approval. Some forecasts project an average price of $4.5825 for 2025, while others have a much more aggressive one-year price target as high as $20.40. That's a huge spread, so you have to decide which side of the risk/reward spectrum you believe. You need to read the full story on the company's financials to make a call on that. Breaking Down Creative Medical Technology Holdings, Inc. (CELZ) Financial Health: Key Insights for Investors

• P/E Ratio (TTM): -1.03x (Not meaningful due to losses)
• P/B Ratio (TTM): 1.41 (Trading slightly above book value)
• EV/EBITDA (TTM): Not Applicable (Negative EBITDA of -$5.97M)
• 12-Month Stock Change: Up 10.97%
• Analyst Consensus: Reduce

Risk Factors

You're looking at Creative Medical Technology Holdings, Inc. (CELZ), a clinical-stage biotech, and the first thing to understand is that the risk profile is high, which is typical for this sector. The company is still very much in the investment phase, meaning financial health hinges on clinical milestones and capital raises, not product sales.

The core financial risk is simple: Creative Medical Technology Holdings, Inc. is burning cash to fund its research and development pipeline. The net loss for the nine months ended September 30, 2025, was $4.11 million, an increase from the $3.64 million loss in the same period a year prior. This is a clear operational risk-it shows the cost of advancing their programs is rising faster than their minimal revenue of just $3,000 year-to-date.

• Financial Runway: While the company reported total cash of $5.38 million at the end of the third quarter of 2025, that cash is finite against a TTM (trailing-twelve-month) net loss of approximately $6.1 million.
• Liquidity Dependence: The company relies on capital market transactions. They recently secured approximately $4.2 million in gross proceeds from the exercise of warrants in October 2025, which helps, but this funding method dilutes existing shareholders.
• High Financial Distress: The Altman Z Score, a measure of corporate distress, is a deeply concerning -4.29, which signals a very high risk of financial instability.

Honestly, the market reflects this uncertainty. The stock is considered 'very high risk' due to its volatility, and insider sentiment has been negative, with high-impact open-market selling totaling $280.9 thousand over the last year, compared to $179.5 thousand in purchases. This tells you key executives are taking some money off the table.

External and Strategic Headwinds

The external risks are classic biotech challenges. First, there's the long, uncertain road to profitability. Analysts anticipate Creative Medical Technology Holdings, Inc. will not breakeven until 2027, and that relies on achieving an extremely buoyant average annual growth rate of 62%. If clinical trials hit a snag, that timeline-and the entire investment thesis-gets pushed back.

Second, the regulatory landscape is a constant hurdle. Their lead program, CELZ-201-DDT for chronic lower back pain, has the significant advantage of an FDA Fast Track Designation, which is a big deal for accelerating development. But Fast Track doesn't guarantee approval, and failure in a Phase I/II trial, like the ADAPT Trial, would be a major setback.

Here's the quick map of risks and mitigation:

The company is defintely trying to de-risk by diversifying and building an intellectual property (IP) fortress. They've launched the BioDefense Inc. Veterans Initiative, a new strategic pivot that uses AI and their proprietary technology to tackle burn pit exposure, which could open a new, government-aligned revenue stream. This is a smart move to broaden their market beyond traditional clinical trials. To dig deeper into who is betting on these strategic moves, you should be Exploring Creative Medical Technology Holdings, Inc. (CELZ) Investor Profile: Who's Buying and Why?

Growth Opportunities

You're looking at Creative Medical Technology Holdings, Inc. (CELZ) and wondering where the real money will come from. The short answer is that near-term value is tied to clinical milestones, not current sales, but the long-term potential is built on an IP-fortified regenerative medicine platform. The company's revenue for the 2025 fiscal year is minimal, reported at a trailing twelve months (TTM) of only $6,000, which is typical for a clinical-stage biotech. However, analysts project a staggering annual revenue growth rate of 1,586%, reflecting the high-risk, high-reward nature of their pipeline.

The company is still in the cash-burn phase, with the average analyst forecast for 2025 earnings (net loss) sitting at approximately -$7,896,428. This is why the $4.2 million in gross proceeds secured from warrant exercises in late October 2025 is so defintely crucial; it provides working capital to push their key programs toward those pivotal 2026 data readouts.

Key Growth Drivers: Clinical Milestones and Product Innovations

Creative Medical Technology Holdings, Inc.'s growth is driven by three core regenerative medicine platforms: AlloStem™, ImmCelz™, and iPScelz. These are not incremental improvements; they are disruptive technologies aiming at multi-billion-dollar markets.

The most significant near-term catalysts are tied to two FDA-cleared clinical programs:

• CELZ-201-DDT (ADAPT Trial): Targeting chronic lower back pain from degenerative disc disease, an estimated $11 billion annual market. This trial received FDA Fast Track Designation in August 2025, which should accelerate development and regulatory review.
• CELZ-201 (CREATE-1 Trial): Focuses on new-onset Type 1 diabetes, leveraging the same AlloStem foundation as the ADAPT trial for cost efficiency.

Topline results for the ADAPT trial are anticipated in the first half of 2026, and early data for the CREATE-1 trial is also expected in 2026. This is the quick math: successful Phase I/II data in either indication could massively re-rate the stock, far outweighing the current $6,000 revenue base.

Strategic Partnerships and Competitive Advantages

The company is not just relying on its internal science; it is strategically positioning itself with key partnerships and a formidable intellectual property (IP) portfolio. This is how a small biotech competes with giants.

The competitive advantage is clear:

• IP Fortress: The company holds an IP portfolio of over 60 patents and pending applications. Two cornerstone U.S. patents for the ImmCelz™ platform were secured in Q3 2025, extending protection for Type 1 Diabetes and Heart Failure applications until 2043 and 2042, respectively. That's long-term exclusivity.
• AI Integration: The expanded partnership with Greenstone Biosciences, announced in February 2025, integrates Artificial Intelligence (AI) into the iPScelz platform to refine hypoimmune iPSC lines for diabetes treatment. This AI-driven approach aims to overcome the major challenge of immunosuppression in stem cell therapies.
• Market Expansion: The launch of the BioDefense Inc. Veterans Initiative in October 2025, in partnership with Greenstone Biosciences, opens a new, mission-critical market-biodefense and veteran health security-by applying their iPSC and AI analytics to toxic burn pit exposure.

What this estimate hides is the binary risk of clinical trials. The downside is a failed trial; the upside is a multi-billion-dollar market. You can explore the investor base further in Exploring Creative Medical Technology Holdings, Inc. (CELZ) Investor Profile: Who's Buying and Why?

Here is a summary of the core pipeline and market targets:

Your next step is to monitor news flow for the Q4 2025 earnings release and, more critically, any updates on the ADAPT trial's path to the anticipated H1 2026 data readout.